Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02073812 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects
A Phase 1 study, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company).
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02073812 is a Phase 1 study that has completed, run by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company). The registered enrollment target is 26 participants.
The verdict
NCT02073812, a Phase 1 study, has completed, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
RPX7009(beta-lactamase inhibitor) is being studied in combination with a carbapenem (RPX2014) to treat bacterial infections, including those due to multi-drug resistant bacteria.
Interventions
- DRUG RPX7009 and RPX2014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02073812
The ClinicalTrials.gov registry entry for NCT02073812 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RPX7009 and RPX2014 is the first listed.
NCT02073812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02073812 about?
NCT02073812 is a clinical study titled "Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects". RPX7009(beta-lactamase inhibitor) is being studied in combination with a carbapenem (RPX2014) to treat bacterial infections, including those due to multi-drug resistant bacteria.
What is the current status of trial NCT02073812?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02073812?
The interventions under investigation include: RPX7009 and RPX2014 (DRUG).
Who is sponsoring clinical trial NCT02073812?
This trial is sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.